高级检索
当前位置: 首页 > 详情页

Higher plasma NT-proBNP levels correlate with syndrome of inappropriate antidiuretic hormone and poor prognosis in neurological patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Merck Serono China Co Ltd, Chengdu, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Peoples R China
出处:
ISSN:

关键词: N-terminal pro-brain natriuretic peptide (NT-proBNP) hyponatremia syndrome of inappropriate antidiuretic hormone (SIADH)

摘要:
Background: Hyponatremia induced by syndrome of inappropriate antidiuretic hormone secretion (SIADH) was common electrolyte disturbance encountered in critically ill neurological diseases, which has normal or increased fluid volume. Brain natriuretic peptide (BNP), which is released in equal proportion to N-terminal pro-brain natriuretic peptide (NT-proBNP), plays vital roles in regulation of volume status. The relationship between SIADH and NT-proBNP levels in neurological diseases has rarely been reported. Methods: A retrospective cross-sectional study was conducted to analyze plasma NT-proBNP levels in 33 patients with SIADH and 23 controlled eunatremic patients with neurological diseases. Results: Baseline NT-proBNP levels were compared between two groups [SIADH group: median 311 pg/mL, interquartile range (IQR) 110-768 pg/mL] vs. eunatremic group: median 46 pg/mL, IQR, 12-96 pg/mL) (P<0.05). Plasma NT-proBNP levels were markedly increased in hyponatremic patients who had two or more complications than those who had less complication (P<0.05). In SIADH patients, NT-proBNP levels in remission phase were lower to levels at baseline. Furthermore, no death was seen in eunatremic patients, while five SIADH patients died from complications. Conclusions: SIADH had higher plasma NT-proBNP levels and poorer prognosis compared to eunatremic neurological patients. NT-proBNP serves as a biomarker of disease severity while not extracellular volume (ECV) status in critically ill neurological patients.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2019]版:
Q2 ONCOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Merck Serono China Co Ltd, Chengdu, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Peoples R China
通讯作者:
通讯机构: [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Peoples R China [*1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol,Branch Natl Clin Res Ctr Metab Di, 1095 Jiefang Rd, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)